Member News
Gambling’s Dopamine Pathway to Addiction
“I say yes to participate in research because it is a way to engage in my community and support other people.” – NATE*, VANCOUVER For Nate*, the many gambling facilities… Read More
Member News
WELL Ventures Reports a New Investment and Successful Follow-on Fundraising Activity in its Portfolio with High Quality Capital Allocators
WELL Ventures is pleased to report that its portfolio companies continue to raise funds at attractive valuations with high quality capital allocators globally. Sun Life has invested $9.5 million in… Read More
Member News
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
– Results of pivotal confirmatory trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall survival and progression-free survival vs standard platinum containing chemotherapy– – If approved, the combination… Read More
Member News
Helping Life Science Firms Navigate the Complex PFAS Risk Landscape
Perfluoroalkyl and polyfluoroalkyl substances, commonly referred to as PFAS, are attracting increasing levels of attention owing to their possible association with human health concerns[1]. This family of over 15,000 substances,… Read More
Member News
Zymeworks Announces Participation In Upcoming Investor Conference
VANCOUVER, BC — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, announced that management will participate in an upcoming investor conference: 42nd Annual J.P. Morgan Healthcare Conference: Zymeworks’… Read More